Expertise in
22
conditions

Dr. Dennis R. Scribner

Gynecologic Oncology | Oncology
Valley Perinatal Services LLC
5605 W Eugie Ave, Suite 111, 
Glendale, AZ 
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
Valley Perinatal Services LLC
5605 W Eugie Ave, Suite 111, 
Glendale, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dennis Scribner is a Gynecologic Oncologist and an Oncologist in Glendale, Arizona. Dr. Scribner is highly rated in 22 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Vaginectomy, and Bladder Reconstruction. Dr. Scribner is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Licenses
Obstetrics & Gynecology in VA
Hospital Affiliations
Yavapai Regional Medical Center
Honorhealth Scottsdale Shea Medical Center
Honorhealth Scottsdale Thompson Peak Med Ctr
Abrazo Arrowhead Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

VALLEY PERINATAL SERVICES LLC
5605 W Eugie Ave, Suite 111, Glendale, AZ 85304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
View 4 Less Clinical Trials

3 Total Publications

Single-site laparoscopic management of a large adnexal mass.
Single-site laparoscopic management of a large adnexal mass.
Journal: JSLS : Journal of the Society of Laparoendoscopic Surgeons
Published: August 09, 2013
Similar Doctors
Expertise in
33
conditions
Dr. Lyndsay J. Willmott
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
33
conditions
Dr. Lyndsay J. Willmott
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Honorhealth Ambulatory

7695 S Research Dr, 
Tempe, AZ 
 (24.3 miles away)
855-485-4673
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Lyndsay Willmott is a Gynecologic Oncologist and an Oncologist in Tempe, Arizona. Dr. Willmott is highly rated in 33 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, and Bladder Reconstruction. Dr. Willmott is currently accepting new patients.

Expertise in
24
conditions
Dr. Mike F. Janicek
Gynecologic Oncology | Oncology
Expertise in
24
conditions
Dr. Mike F. Janicek
Gynecologic Oncology | Oncology

Honorhealth Ambulatory

10197 N 92nd St, Suite 101, 
Scottsdale, AZ 
 (17.5 miles away)
480-270-5309
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Mike Janicek is a Gynecologic Oncologist and an Oncologist in Scottsdale, Arizona. Dr. Janicek is highly rated in 24 conditions, according to our data. His top areas of expertise are Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, Ovarian Cancer, Oophorectomy, and Hernia Surgery. Dr. Janicek is currently accepting new patients.

Expertise in
17
conditions
Dr. Snehal M. Bhoola
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Expertise in
17
conditions
Dr. Snehal M. Bhoola
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

City Of Hope Medical Group Of Arizona LLC

14200 W Celebrate Life Way, 
Goodyear, AZ 
 (14.9 miles away)
623-207-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Snehal Bhoola is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Goodyear, Arizona. Dr. Bhoola is highly rated in 17 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Bladder Reconstruction, and Oophorectomy. Dr. Bhoola is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Scribner's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile